当前位置: 首页 >> 检索结果
281. Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial.
作者: Kim A Connelly.;C David Mazer.;Pankaj Puar.;Hwee Teoh.;Chao-Hung Wang.;Tamique Mason.;Farhad Akhavein.;Ching-Wen Chang.;Min-Hui Liu.;Ning-I Yang.;Wei-Siang Chen.;Yu-Hsiang Juan.;Erika Opingari.;Yaseen Salyani.;William Barbour.;Aryan Pasricha.;Shamon Ahmed.;Andrew Kosmopoulos.;Raj Verma.;Michael Moroney.;Ehab Bakbak.;Aishwarya Krishnaraj.;Deepak L Bhatt.;Javed Butler.;Mikhail N Kosiborod.;Carolyn S P Lam.;David A Hess.;Otavio Rizzi Coelho-Filho.;Myriam Lafreniere-Roula.;Kevin E Thorpe.;Adrian Quan.;Lawrence A Leiter.;Andrew T Yan.;Subodh Verma.
来源: Circulation. 2023年147卷4期284-295页
Sodium-glucose cotransporter 2 inhibitors have been demonstrated to promote reverse cardiac remodeling in people with diabetes or heart failure. Although it has been theorized that sodium-glucose cotransporter 2 inhibitors might afford similar benefits in people without diabetes or prevalent heart failure, this has not been evaluated. We sought to determine whether sodium-glucose cotransporter 2 inhibition with empagliflozin leads to a decrease in left ventricular (LV) mass in people without type 2 diabetes or significant heart failure.
282. Decongestion With Acetazolamide in Acute Decompensated Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction: A Prespecified Analysis From the ADVOR Trial.
作者: Pieter Martens.;Jeroen Dauw.;Frederik H Verbrugge.;Petra Nijst.;Evelyne Meekers.;Silvio Nunes Augusto.;Jozine M Ter Maaten.;Kevin Damman.;Alexandre Mebazaa.;Gerasimos Filippatos.;Frank Ruschitzka.;W H Wilson Tang.;Matthias Dupont.;Wilfried Mullens.
来源: Circulation. 2023年147卷3期201-211页
Acetazolamide inhibits proximal tubular sodium reabsorption and improved decongestion in the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume Overload) trial. It remains unclear whether the decongestive effects of acetazolamide differ across the spectrum of left ventricular ejection fraction (LVEF).
283. Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Results of the ECMO-CS Randomized Clinical Trial.
作者: Petr Ostadal.;Richard Rokyta.;Jiri Karasek.;Andreas Kruger.;Dagmar Vondrakova.;Marek Janotka.;Jan Naar.;Jana Smalcova.;Marketa Hubatova.;Milan Hromadka.;Stefan Volovar.;Miroslava Seyfrydova.;Jiri Jarkovsky.;Michal Svoboda.;Ales Linhart.;Jan Belohlavek.; .
来源: Circulation. 2023年147卷6期454-464页
Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is increasingly being used for circulatory support in patients with cardiogenic shock, although the evidence supporting its use in this context remains insufficient. The ECMO-CS trial (Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock) aimed to compare immediate implementation of VA-ECMO versus an initially conservative therapy (allowing downstream use of VA-ECMO) in patients with rapidly deteriorating or severe cardiogenic shock.
284. Impact of Patient-Reported Outcome Measurement in Heart Failure Clinic on Clinician Health Status Assessment and Patient Experience: A Substudy of the PRO-HF Trial.
作者: Alexander T Sandhu.;Jimmy Zheng.;Neil M Kalwani.;Anshal Gupta.;Jamie Calma.;Megan Skye.;Roy Lan.;Brian Yu.;John A Spertus.;Paul A Heidenreich.
来源: Circ Heart Fail. 2023年16卷2期e010280页
Clinicians typically estimate heart failure health status using the New York Heart Association Class, which is often discordant with patient-reported health status. It is unknown whether collecting patient-reported health status improves the accuracy of clinician assessments.
285. The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial.
作者: Roxana Mehran.;Philippe Gabriel Steg.;Marc A Pfeffer.;Karola Jering.;Brian Claggett.;Eldrin F Lewis.;Christopher Granger.;Lars Køber.;Aldo Maggioni.;Douglas L Mann.;John J V McMurray.;Jean-Lucien Rouleau.;Scott D Solomon.;Gregory Ducrocq.;Otavio Berwanger.;Carmine G De Pasquale.;Ulf Landmesser.;Mark Petrie.;David Sim Kheng Leng.;Peter van der Meer.;Martin Lefkowitz.;Yinong Zhou.;Eugene Braunwald.
来源: Circulation. 2022年146卷23期1749-1757页
In patients who survive an acute myocardial infarction (AMI), angiotensin-converting enzyme inhibitors decrease the risk of subsequent major cardiovascular events. Whether angiotensin-receptor blockade and neprilysin inhibition with sacubitril/valsartan reduce major coronary events more effectively than angiotensin-converting enzyme inhibitors in high-risk patients with recent AMI remains unknown. We aimed to compare the effects of sacubitril/valsartan on coronary outcomes in patients with AMI.
286. Enhancing Sweat Rate Using a Novel Device for the Treatment of Congestion in Heart Failure.
作者: Doron Aronson.;Yaacov Nitzan.;Sirouch Petcherski.;Evgeny Bravo.;Manhal Habib.;Daniel Burkhoff.;William T Abraham.
来源: Circ Heart Fail. 2023年16卷1期e009787页
Current treatment of fluid retention in heart failure relies primarily on diuretics. However, adequate decongestion is not achieved in many patients. We aimed to study the feasibility and short-term performance of a novel approach to remove fluids and sodium directly from the interstitial compartment by enhancing sweat rate.
287. In-Hospital Virtual Peer-to-Peer Consultation to Increase Guideline-Directed Medical Therapy for Heart Failure: A Pilot Randomized Trial.
作者: Vishal N Rao.;Anand Shah.;Jaime McDermott.;Stephanie G Barnes.;Evan M Murray.;Michelle D Kelsey.;Stephen J Greene.;Marat Fudim.;Adam D DeVore.;Chetan B Patel.;Michael A Blazing.;Cara O'Brien.;Robert J Mentz.
来源: Circ Heart Fail. 2023年16卷2期e010158页
Guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) improves clinical outcomes and quality of life. Optimizing GDMT in the hospital is associated with greater long-term use in HFrEF. This study aimed to describe the efficacy of a multidisciplinary virtual HF intervention on GDMT optimization among patients with HFrEF admitted for any cause.
288. Comparing New York Heart Association Class and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure.
作者: Michael F Cosiano.;Andrew Vista.;Jie-Lena Sun.;Brooke Alhanti.;Josephine Harrington.;Javed Butler.;Randall C Starling.;Robert J Mentz.;Stephen J Greene.
来源: Circ Heart Fail. 2023年16卷1期e010107页
Alignment between clinician-reported New York Heart Association (NYHA) class compared and patient-reported outcomes among patients hospitalized for heart failure is unclear.
289. A Randomized, Controlled Trial of Resistance Training Added to Caloric Restriction Plus Aerobic Exercise Training in Obese Heart Failure With Preserved Ejection Fraction.
作者: Peter H Brubaker.;Barbara J Nicklas.;Denise K Houston.;W Gregory Hundley.;Haiying Chen.;Anthony J A Molina.;W Mary Lyles.;Benjamin Nelson.;Bharathi Upadhya.;Russell Newland.;Dalane W Kitzman.
来源: Circ Heart Fail. 2023年16卷2期e010161页
We have shown that combined caloric restriction (CR) and aerobic exercise training (AT) improve peak exercise O2 consumption (VO2peak), and quality-of-life in older patients with obese heart failure with preserved ejection fraction. However, ≈35% of weight lost during CR+AT was skeletal muscle mass. We examined whether addition of resistance training (RT) to CR+AT would reduce skeletal muscle loss and further improve outcomes.
290. Long-Term Mortality Follow-Up of Radial Artery Versus Saphenous Vein in Coronary Artery Bypass Grafting: A Multicenter, Randomized Trial.
作者: Steven Goldman.;Madeline McCarren.;Gulshan K Sethi.;William Holman.;Faisal G Bakaeen.;Todd H Wagner.;Yajie Wang.;Mei-Chung Shih.;Robert Edson.; .
来源: Circulation. 2022年146卷17期1323-1325页 291. Economics of Minimalist Transcatheter Aortic Valve Replacement: Results From the 3M-TAVR Economic Study.
作者: Neel M Butala.;David A Wood.;Haiyan Li.;Khaja Chinnakondepalli.;Sandra B Lauck.;Janarthanan Sathananthan.;John A Cairns.;Elizabeth A Magnuson.;Madeleine Barker.;John G Webb.;Robert Welsh.;Anson Cheung.;Jian Ye.;James L Velianou.;Harindra C Wijeysundera.;Anita Asgar.;Susheel Kodali.;Vinod H Thourani.;David J Cohen.; .
来源: Circ Cardiovasc Interv. 2022年15卷10期e012168页
The 3M-TAVR trial (3M-Transcatheter Aortic Valve Replacement) demonstrated the feasibility and safety of next-day hospital discharge after transfemoral TAVR with implementation of a minimalist pathway. However, the economic impact of this approach is unknown. Therefore, we evaluated costs for patients undergoing minimalist TAVR compared with conventional TAVR.
292. Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome and High Bleeding Risk.
作者: Shqipdona Lahu.;Antonia Presch.;Gjin Ndrepepa.;Maurizio Menichelli.;Christian Valina.;Rayyan Hemetsberger.;Bernhard Witzenbichler.;Isabell Bernlochner.;Michael Joner.;Erion Xhepa.;Alexander Hapfelmeier.;Sebastian Kufner.;Nonglag Rifatov.;Hendrik B Sager.;Katharina Mayer.;Thorsten Kessler.;Karl-Ludwig Laugwitz.;Gert Richardt.;Heribert Schunkert.;Franz-Josef Neumann.;Dirk Sibbing.;Dominick J Angiolillo.;Adnan Kastrati.;Salvatore Cassese.
来源: Circ Cardiovasc Interv. 2022年15卷10期e012204页
The relative efficacy and safety of more potent P2Y12 inhibitors in patients with acute coronary syndrome and high bleeding risk (HBR) undergoing percutaneous coronary intervention remains unclear. We aimed to study the treatment effect of ticagrelor and prasugrel in percutaneous coronary intervention patients presenting with acute coronary syndrome and HBR.
293. Efficacy of a Drug-Eluting Stent Versus Bare Metal Stents for Symptomatic Femoropopliteal Peripheral Artery Disease: Primary Results of the EMINENT Randomized Trial.
作者: Yann Gouëffic.;Giovanni Torsello.;Thomas Zeller.;Giovanni Esposito.;Frank Vermassen.;Klaus Armin Hausegger.;Gunnar Tepe.;Marcus Thieme.;Michael Gschwandtner.;Andrea Kahlberg.;Marc Schindewolf.;Marc Sapoval.;Juan Diaz-Cartelle.;Konstantinos Stavroulakis.; .
来源: Circulation. 2022年146卷21期1564-1576页
A clear patency benefit of a drug-eluting stent (DES) over bare metal stents (BMSs) for treating peripheral artery disease of the femoropopliteal segment has not been definitively demonstrated. The EMINENT study (Trial Comparing Eluvia Versus Bare Metal Stent in Treatment of Superficial Femoral and/or Proximal Popliteal Artery) was designed to evaluate the patency of the Eluvia DES (Boston Scientific, Marlborough, MA), a polymer-coated paclitaxel-eluting stent, compared with BMSs for the treatment of femoropopliteal artery lesions.
294. Machine Learning From Quantitative Coronary Computed Tomography Angiography Predicts Fractional Flow Reserve-Defined Ischemia and Impaired Myocardial Blood Flow.
作者: Andrew Lin.;Pepijn A van Diemen.;Manish Motwani.;Priscilla McElhinney.;Yuka Otaki.;Donghee Han.;Alan Kwan.;Evangelos Tzolos.;Eyal Klein.;Keiichiro Kuronuma.;Kajetan Grodecki.;Benjamin Shou.;Richard Rios.;Nipun Manral.;Sebastien Cadet.;Ibrahim Danad.;Roel S Driessen.;Daniel S Berman.;Bjarne L Nørgaard.;Piotr J Slomka.;Paul Knaapen.;Damini Dey.
来源: Circ Cardiovasc Imaging. 2022年15卷10期e014369页
A pathophysiological interplay exists between plaque morphology and coronary physiology. Machine learning (ML) is increasingly being applied to coronary computed tomography angiography (CCTA) for cardiovascular risk stratification. We sought to assess the performance of a ML score integrating CCTA-based quantitative plaque features for predicting vessel-specific ischemia by invasive fractional flow reserve (FFR) and impaired myocardial blood flow (MBF) by positron emission tomography (PET).
295. Impact of Different Training Modalities on Molecular Alterations in Skeletal Muscle of Patients With Heart Failure With Preserved Ejection Fraction: A Substudy of the OptimEx Trial.
作者: Ephraim B Winzer.;Antje Augstein.;Antje Schauer.;Stephan Mueller.;Tina Fischer-Schaepmann.;Keita Goto.;Jennifer Hommel.;Emeline M van Craenenbroeck.;Ulrik Wisløff.;Burkert Pieske.;Martin Halle.;Axel Linke.;Volker Adams.
来源: Circ Heart Fail. 2022年15卷10期e009124页
Exercise intolerance is a cardinal feature of heart failure with preserved ejection fraction and so far exercise training (ET) is the most effective treatment. Since the improvement in exercise capacity is only weakly associated with changes in diastolic function other mechanisms, like changes in the skeletal muscle, contribute to improvement in peak oxygen consumption. The aim of the present study was to analyze molecular changes in skeletal muscle of patients with heart failure with preserved ejection fraction performing different ET modalities.
296. Guideline-Directed Medical Therapy Attainment and Outcomes in Dialysis-Requiring Versus Nondialysis Chronic Kidney Disease in the ISCHEMIA-CKD Trial.
作者: Roy O Mathew.;David J Maron.;Rebecca Anthopolos.;Jerome L Fleg.;Sean M O'Brien.;Frank W Rockhold.;Carlo Briguori.;Marek F Roik.;Tomasz Mazurek.;Marcin Demkow.;Robert Malecki.;Zhiming Ye.;Upendra Kaul.;Marius Miglinas.;Gregg W Stone.;Ron Wald.;David M Charytan.;Mandeep S Sidhu.;Judith S Hochman.;Sripal Bangalore.
来源: Circ Cardiovasc Qual Outcomes. 2022年15卷10期e008995页
Patients with chronic kidney disease (CKD) on dialysis (CKD G5D) have worse cardiovascular outcomes than patients with advanced nondialysis CKD (CKD G4-5: estimated glomerular filtration rate <30 mL/[min·1.73m2]). Our objective was to evaluate the relationship between achievement of cardiovascular guideline-directed medical therapy (GDMT) goals and clinical outcomes for CKD G5D versus CKD G4-5.
297. Preventive Effect of Berberine on Postoperative Atrial Fibrillation.
作者: Jian Zhang.;Yang Wang.;Hui Jiang.;Dengshun Tao.;Keyan Zhao.;Zongtao Yin.;Jinsong Han.;Fangran Xin.;Yan Jin.;Huishan Wang.
来源: Circ Arrhythm Electrophysiol. 2022年15卷10期e011160页
Postoperative atrial fibrillation (POAF) is one of the most common complications of cardiac surgery, but the underlying factors governing POAF are not well understood. The aim of this study was to investigate the efficacy of berberine administration on POAF.
298. Temperature Control After In-Hospital Cardiac Arrest: A Randomized Clinical Trial.
作者: Sebastian Wolfrum.;Kevin Roedl.;Alexia Hanebutte.;Rüdiger Pfeifer.;Volkhard Kurowski.;Reimer Riessen.;Anne Daubmann.;Stephan Braune.;Gerold Söffker.;Eric Bibiza-Freiwald.;Karl Wegscheider.;Heribert Schunkert.;Holger Thiele.;Stefan Kluge.; .
来源: Circulation. 2022年146卷18期1357-1366页
This study was conducted to determine the effect of hypothermic temperature control after in-hospital cardiac arrest (IHCA) on mortality and functional outcome as compared with normothermia.
299. A Mechanistic Clinical Trial Using (R)- Versus (S)-Propafenone to Test RyR2 (Ryanodine Receptor) Inhibition for the Prevention of Atrial Fibrillation Induction.
作者: M Benjamin Shoemaker.;Zachary T Yoneda.;Diane M Crawford.;Wendell S Akers.;Travis Richardson.;Jay A Montgomery.;Sharon Phillips.;Yu Shyr.;Pablo Saavedra.;Juan C Estrada.;Arvindh Kanagasundram.;Sharon T Shen.;Gregory F Michaud.;George Crossley.;Christopher R Ellis.;Bjorn C Knollmann.
来源: Circ Arrhythm Electrophysiol. 2022年15卷10期e010713页
Experimental data suggest ryanodine receptor-mediated intracellular calcium leak is a mechanism for atrial fibrillation (AF), but evidence in humans is still needed. Propafenone is composed of two enantiomers that are equally potent sodium-channel blockers; however, (R)-propafenone is an ryanodine receptor inhibitor whereas (S)-propafenone is not. This study tested the hypothesis that ryanodine receptor inhibition with (R)-propafenone prevents induction of AF compared to (S)-propafenone or placebo in patients referred for AF ablation.
300. Proteomic Analysis of Effects of Spironolactone in Heart Failure With Preserved Ejection Fraction.
作者: Ali Javaheri.;Ahmed Diab.;Lei Zhao.;Chenao Qian.;Jordana B Cohen.;Payman Zamani.;Anupam Kumar.;Zhaoqing Wang.;Christina Ebert.;Joseph Maranville.;Erika Kvikstad.;Michael Basso.;Vanessa van Empel.;A Mark Richards.;Robert N Doughty.;Ernst Rietzschel.;Karl Kammerhoff.;Joseph Gogain.;Peter Schafer.;Dietmar A Seiffert.;David A Gordon.;Francisco Ramirez-Valle.;Douglas L Mann.;Thomas P Cappola.;Julio A Chirinos.
来源: Circ Heart Fail. 2022年15卷9期e009693页
The TOPCAT trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial) suggested clinical benefits of spironolactone treatment among patients with heart failure with preserved ejection fraction enrolled in the Americas. However, a comprehensive assessment of biologic pathways impacted by spironolactone therapy in heart failure with preserved ejection fraction has not been performed.
|